The “Sake & Science: Advances in multiomics for biomarker discovery” event on June 5, 2025, blended the elegance of Japanese tradition with cutting-edge scientific innovation.
At the symposium, attendees sipped on world-famous Takara sake and learned about new approaches that capture unique insights into cellular function and dysfunction. Distinguished guest speakers shared their groundbreaking research on cellular signatures in heart failure, the spatiotemporal evolution of cancer, novel RNA liquid biopsy technology, and other fascinating topics.
Decoding early synovial joint development with single‑cell and spatial transcriptomics
Integration of single-cell multi-omics data from cardiac biopsies in heart failure
Tracing the spatiotemporal evolution of cancer
Cracking HFpEF: deep cellular signatures of dysfunction and recovery in failing hearts
Nanopore sequencing enables esophageal cancer early detection via RNA liquid biopsy
Dr. Jones discusses the use of new genomic and imaging technologies to address long-standing questions about tumor evolution. He is working to discover stereotypical paths that tumors take to evolve, which could be targeted in a patient’s therapeutic journey. His work relies on mind-blowing technologies that democratize previously inaccessible investigative approaches.
Dr. Kim shares his experience in developing RNA-based liquid biopsies that have the potential to detect biomarkers of cancer—and even precancer—in the early stages of disease when treatments are most effective. His lab’s reliance on Takara Bio’s molecular biology reagents underscores the importance of high-quality tools in driving cutting-edge transcriptomics research.
Dr. Farshidfar explains his work towards developing treatment modalities for genetic cardiomyopathies and other cardiac diseases. New technologies are enabling the exploration of what was previously impossible—the activity and interactions of different cell types in a functioning heart. When combined with the explosion in patient data, he sees real potential to improve patient outcomes.
Eexciting new single-cell NGS technologies to usher in an era of novel biomarker discovery.
This technical note describes how researchers can perform single-cell DNA-seq with the Shasta Whole-Genome Amplification Kit.
This technical note describes how researchers can obtain high throughput and sensitivity for full gene-body transcriptome analysis at the single-cell level with the Shasta Total RNA-Seq Kit.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2025 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
©2025 Takara Bio Inc. All Rights Reserved.
Region - North America Privacy Policy Terms and Conditions Terms of Use
Interview with Matthew Jones, PhD, Postdoctoral Fellow, Stanford University
Dr. Jones discusses the use of new genomic and imaging technologies to address long-standing questions about tumor evolution. He is working to discover stereotypical paths that tumors take to evolve, which could be targeted in a patient’s therapeutic journey. His work relies on mind-blowing technologies that democratize previously inaccessible investigative approaches.
Interview with Daniel Kim, PhD, Assistant Professor, UC Santa Cruz
Dr. Kim shares his experience in developing RNA-based liquid biopsies that have the potential to detect biomarkers of cancer—and even precancer—in the early stages of disease when treatments are most effective. His lab’s reliance on Takara Bio’s molecular biology reagents underscores the importance of high-quality tools in driving cutting-edge transcriptomics research.
Interview with Farshad Farshidfar, MD, PhD, Senior Scientist, Tenaya Therapeutics
Dr. Farshidfar explains his work towards developing treatment modalities for genetic cardiomyopathies and other cardiac diseases. New technologies are enabling the exploration of what was previously impossible—the activity and interactions of different cell types in a functioning heart. When combined with the explosion in patient data, he sees real potential to improve patient outcomes.